Acarix As Stock Current Valuation
| ACARIX Stock | SEK 0.27 0.01 3.85% |
Valuation analysis of Acarix AS helps investors to measure Acarix AS's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns.
Overvalued
Today
Please note that Acarix AS's price fluctuation is out of control at this time. Calculation of the real value of Acarix AS is based on 3 months time horizon. Increasing Acarix AS's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Acarix AS is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Acarix Stock. However, Acarix AS's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.27 | Real 0.21 | Hype 0.27 |
The real value of Acarix Stock, also known as its intrinsic value, is the underlying worth of Acarix AS Company, which is reflected in its stock price. It is based on Acarix AS's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Acarix AS's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Acarix AS helps investors to forecast how Acarix stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Acarix AS more accurately as focusing exclusively on Acarix AS's fundamentals will not take into account other important factors: Acarix AS Company Current Valuation Analysis
Acarix AS's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Acarix AS Current Valuation | 51.77 M |
Most of Acarix AS's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acarix AS is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Acarix AS has a Current Valuation of 51.77 M. This is 99.64% lower than that of the Health Care Equipment & Supplies sector and 99.58% lower than that of the Health Care industry. The current valuation for all Sweden stocks is 99.69% higher than that of the company.
Acarix Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acarix AS's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acarix AS could also be used in its relative valuation, which is a method of valuing Acarix AS by comparing valuation metrics of similar companies.Acarix AS is currently under evaluation in current valuation category among its peers.
Acarix Fundamentals
| Return On Equity | -1.46 | |||
| Return On Asset | -0.8 | |||
| Operating Margin | (13.75) % | |||
| Current Valuation | 51.77 M | |||
| Shares Outstanding | 373.33 M | |||
| Shares Owned By Insiders | 10.28 % | |||
| Shares Owned By Institutions | 2.84 % | |||
| Price To Book | 1.63 X | |||
| Price To Sales | 15.38 X | |||
| Revenue | 3.76 M | |||
| Gross Profit | 2.82 M | |||
| EBITDA | (48.28 M) | |||
| Net Income | (51.73 M) | |||
| Cash And Equivalents | 15.86 M | |||
| Cash Per Share | 2.24 X | |||
| Total Debt | 239 K | |||
| Debt To Equity | 2.30 % | |||
| Current Ratio | 7.38 X | |||
| Book Value Per Share | 0.20 X | |||
| Cash Flow From Operations | (48.01 M) | |||
| Earnings Per Share | (0.31) X | |||
| Target Price | 0.75 | |||
| Beta | 1.65 | |||
| Market Capitalization | 107.15 M | |||
| Total Asset | 118.6 M | |||
| Net Asset | 118.6 M |
About Acarix AS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Acarix AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acarix AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acarix AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Acarix Stock
Acarix AS financial ratios help investors to determine whether Acarix Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Acarix with respect to the benefits of owning Acarix AS security.